SEC Form 4 · accession 0001209191-15-019749
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory T Went
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Feb 25, 2015
Accepted (ET)
Feb 27, 2015 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $17.31 | Feb 25, 2015 | A | 75,000 | A | — | Feb 24, 2025 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with March 1, 2015, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.